A comprehensive overview of three classic neurodevelopmental genetic disorders — Tuberous Sclerosis Complex (TSC), Fragile X Syndrome, and Rett Syndrome — covering molecular pathogenesis, clinical recognition, targeted therapies, and genetic testing strategies for each condition.
Tags: Neurogenetics
Tuberous Sclerosis Complex (TSC) is an autosomal dominant multi-system disorder caused by loss-of-function variants in TSC1 (encoding hamartin, chromosome 9q34) or TSC2 (encoding tuberin, chromosome 16p13.3). Hamartin and tuberin form a heterodimeric complex that acts as a critical negative regulator of the mTOR (mechanistic target of rapamycin) pathway. Loss of either protein releases constitutive mTOR activation, driving excessive cell growth and proliferation and producing characteristic hamartomas across multiple organ systems. Approximately two-thirds of TSC cases arise de novo, with no family history. TSC follows a two-hit model of tumorigenesis: patients carry a germline (first hit) pathogenic variant, and somatic loss of heterozygosity or a second somatic hit in the remaining allele drives focal lesion formation in individual tissues.
Key Points
TSC is a paradigm for targeted molecular therapy in neurogenetics. Because the core pathogenic mechanism is constitutive mTOR pathway activation, mTOR inhibitors directly address the molecular defect. Everolimus (an mTOR inhibitor, also called an mTOR complex 1 inhibitor or rapalog) is FDA-approved for multiple TSC indications. In parallel, vigabatrin — an irreversible GABA transaminase inhibitor — has a uniquely preferential efficacy in TSC-associated infantile spasms compared to other etiologies of infantile spasms. The emerging concept of preventive (pre-symptomatic) treatment is transforming TSC management, with evidence suggesting that early intervention before seizure onset may improve neurodevelopmental outcomes.
Key Points
Fragile X Syndrome is the most common inherited cause of intellectual disability and the most common single-gene cause of autism spectrum disorder. It is caused by a CGG trinucleotide repeat expansion in the 5' untranslated region (5'UTR) of the FMR1 gene on Xq27.3. Normal alleles have <45 CGG repeats; intermediate (gray zone) alleles have 45–54 repeats; premutation alleles have 55–200 repeats; and full mutation alleles have >200 repeats. Full mutation alleles trigger hypermethylation of the FMR1 promoter and the CGG repeat region, silencing FMR1 transcription and abolishing production of the fragile X messenger ribonucleoprotein (FMRP). FMRP is an RNA-binding protein essential for mRNA transport and translational regulation at synapses — it is a critical regulator of synaptic plasticity, and its absence causes widespread dysregulation of synaptic protein synthesis.
Key Points
The FMR1 premutation (55–200 CGG repeats) is not clinically silent. Unlike the full mutation — which silences FMR1 via promoter methylation — the premutation results in elevated FMR1 mRNA transcription (2–8 times normal levels) but reduced FMRP protein production. The excess CGG-repeat-containing mRNA is directly toxic through an RNA gain-of-function mechanism: expanded CGG repeat RNA sequesters RNA-binding proteins and forms intranuclear inclusions, causing progressive neurodegeneration (FXTAS) and ovarian dysfunction (FXPOI). This is a fundamentally different pathogenic mechanism from the full mutation, where the gene is silenced and FMRP is absent.
Key Points
Rett Syndrome is an X-linked dominant neurodevelopmental disorder caused by de novo loss-of-function variants in MECP2 (methyl-CpG-binding protein 2, Xq28). It affects almost exclusively females — hemizygous males with complete MECP2 loss of function typically die in infancy or early childhood, though rare male cases occur with somatic mosaicism, Klinefelter syndrome (47,XXY), or hypomorphic variants. Over 95% of MECP2 pathogenic variants in classic Rett are de novo. MECP2 protein binds methylated CpG dinucleotides genome-wide and recruits chromatin remodeling complexes (including the NCoR/SMRT co-repressor complex and the histone deacetylase HDAC3) to regulate transcription — its loss causes widespread transcriptional dysregulation in the brain, particularly in mature neurons where MECP2 is most abundantly expressed.
Key Points
Each of the three neurodevelopmental disorders discussed in this module requires a distinct genetic testing approach, and recognizing which test to order is essential for efficient diagnosis. A common and costly error is assuming that exome or genome sequencing will detect all genetic causes of intellectual disability — it will not, because trinucleotide repeat expansion disorders like Fragile X require dedicated repeat analysis. Understanding the strengths and limitations of each testing modality prevents missed diagnoses and unnecessary delays.
Key Points
1. A 2-year-old girl with normal early development has lost purposeful hand use and spoken words over the past 6 months. She has developed repetitive hand-wringing movements, irregular breathing, and an ataxic gait. Seizures have recently begun. Which genetic test is most likely to confirm the diagnosis?
This presentation — normal early development followed by regression of purposeful hand skills and language (typically 6–18 months of age), with emergence of stereotypic hand movements (wringing, squeezing), breathing dysregulation, ataxia, and seizures — is classic for Rett syndrome. Rett syndrome is caused by de novo heterozygous variants in MECP2 (Xq28), encoding methyl-CpG binding protein 2, and occurs almost exclusively in females. Angelman syndrome presents with absent speech from infancy (not regression), and Fragile X does not feature hand stereotypies or breathing irregularities as cardinal features.
2. A 10-year-old boy with moderate intellectual disability, anxiety, ADHD, prominent ears, and a long face is being evaluated. His maternal grandfather (age 68) has progressive tremor and gait ataxia, and his mother experienced premature menopause at age 36. What single genetic test would you order first?
This family demonstrates the full spectrum of FMR1 repeat expansion disease: the boy has features of Fragile X Syndrome (full mutation: ID, characteristic facies, behavioral features), the maternal grandfather has features of FXTAS (premutation: late-onset tremor and ataxia), and the mother has FXPOI (premutation: premature menopause at 36). FMR1 CGG repeat analysis is the correct test — and critically, this would NOT be detected by standard WES; modern WGS may screen for some STR disorders but dedicated FMR1 repeat analysis remains the gold standard.
3. A genetics trainee orders whole exome sequencing for a 5-year-old boy with intellectual disability, suspecting a genetic diagnosis. The WES returns negative. The boy has moderate ID, prominent ears, hand flapping, gaze avoidance, and joint hypermobility. What critical test was likely omitted?
This boy's clinical features — moderate intellectual disability, prominent ears, hand flapping, gaze avoidance, and joint hypermobility — are classic for Fragile X Syndrome. The critical missed test is FMR1 CGG repeat analysis. Standard WES uses short-read sequencing technology that cannot reliably size large trinucleotide repeat expansions. Fragile X testing must be specifically ordered and is recommended as a first-tier test in any male with unexplained intellectual disability. This is a common and costly diagnostic error.
4. Which of the following best describes the pathogenic mechanism in Fragile X-associated tremor/ataxia syndrome (FXTAS)?
FXTAS is caused by the FMR1 premutation (55–200 CGG repeats), which — unlike the full mutation — does NOT silence the gene. Instead, the premutation produces elevated levels of FMR1 mRNA with expanded CGG repeats. This excess mRNA forms hairpin structures, sequesters RNA-binding proteins (DGCR8, Sam68, hnRNP A2/B1), and forms toxic intranuclear inclusions in neurons and astrocytes. This RNA gain-of-function mechanism is fundamentally different from the full mutation, where the gene is silenced and FMRP is absent.
5. A 2-year-old girl who was developing normally is brought in because she has stopped using her hands purposefully over the past 3 months, lost her 10-word vocabulary, and developed repetitive hand-wringing movements. Head circumference has fallen from the 50th to the 10th percentile. What is the most likely diagnosis?
This presentation is classic for Rett Syndrome (Stage II — Rapid Regression): a previously normally developing girl who loses purposeful hand skills and spoken language, develops stereotypic hand movements (hand-wringing), and shows acquired microcephaly (postnatal deceleration of head growth). Rett Syndrome almost exclusively affects females and is caused by de novo MECP2 variants in >95% of cases. The combination of regression, hand stereotypies, and acquired microcephaly is highly specific for Rett.
6. Why is gene replacement therapy for Rett Syndrome (MECP2) particularly challenging compared to other single-gene disorders?
MECP2 is a dosage-sensitive gene: loss of function causes Rett Syndrome, while duplication (overexpression) causes MECP2 duplication syndrome — a distinct disorder characterized by intellectual disability, seizures, recurrent infections, and progressive spasticity, predominantly in males. This narrow therapeutic window means that gene therapy must achieve expression levels that are neither too low nor too high, which is extremely difficult with current vector technologies. This is a major challenge that distinguishes MECP2 from genes where overexpression is tolerated.